OPTN
- OptiNose, Inc.
()
Overview
Company Summary
OptiNose, Inc. is a pharmaceutical company that focuses on developing and commercializing innovative products for patients suffering from various medical conditions. The company specializes in using its patented Optinose Exhalation Delivery System (EDS) technology to deliver drugs deep into the nasal cavity.
OptiNose's EDS technology is designed to optimize the delivery of medication to the nasal passages, helping to improve the effectiveness of treatment. By targeting the site of action directly, this unique delivery system ensures that the medication reaches the right place at the right dosage, enhancing therapeutic outcomes.
The company primarily works in the field of otolaryngology, targeting conditions such as chronic rhinosinusitis, nasal polyps, and migraines. For instance, their flagship product, XHANCE, is a prescription nasal spray that delivers fluticasone propionate directly to the nasal mucosa. It is designed to treat nasal polyps in adults and help relieve nasal congestion and inflammation.
OptiNose has also developed and commercialized AVP-825 (ONZETRA� Xsail�), a product for the treatment of migraines in patients who have a clear diagnosis of migraine. AVP-825 delivers a low-dose sumatriptan powder intranasally through the Xsail device, enhancing the delivery of the medication to the upper nasal cavity for rapid and effective relief.
The company's mission is to improve the lives of patients by providing innovative, user-friendly, and effective treatments for nasal conditions. They continue to invest in research and development to expand their product portfolio and explore new therapeutic applications for their delivery technology.
Overall, OptiNose focuses on leveraging their proprietary EDS technology to optimize medication delivery, providing targeted solutions for patients suffering from various nasal conditions, including chronic rhinosinusitis, nasal polyps, and migraines.